In the past few decades, great advances have been made in the field of solid-organ transplantation. A greater understanding of immune system function, the development of modern immunosuppression, and advancements in surgical technique have led to marked improvements in both recipient and graft survivals, as well as recipients' quality of life. However, improved survival rates have also led to prolonged exposure to chronic immunosuppression, which increases the risk for the development of posttransplant malignancies. In addition, older transplant candidates are being considered, carrying with them the increased likelihood of pre-existing malignancy. Consequently, the potential risk of posttransplant malignancy must be considered. Moreover, as long-term transplant survivors continue to age, posttransplant malignancies will be seen more frequently. This review presents the more commonly encountered posttransplant malignancies and the measures that are currently being utilized to prevent and treat them.
Get full access to this article
View all access options for this article.
References
1.
LevineAM. Lymphoma complicating immunodeficiency disorders. Ann Oncol.1994;5(suppl 2):29–35.
2.
LevineAMSeneviratneLTulpuleA. Incidence and management of AIDS-related lymphoma. Oncology (Huntingt).2001;15:629–639; discussion 639–640, 645–646.
3.
KinlenLJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. January 1985;78:44–49.
4.
KyllonenLSalmelaKPukkalaE. Cancer incidence in a kidney-transplanted population. Transpl Int.2000;13(suppl 1): S394–398.
5.
PennI. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl.1994;8:99–109.
6.
PennIHammondWBrettschneiderLStarzlTE. Malignant lymphomas in transplantation patients. Transplant Proc. March 1969;1:106–112.
7.
PennI. The effect of immunosuppression on pre-existing cancers. Transplantation.1993;55:742–747.
8.
PennI. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant.1997;2:14–17.
9.
KasiskeBLCangroCBHariharanS. The evaluation of renal transplantation candidates: Clinical practice guidelines. Am J Transplant.2001;1(suppl 2):1–95.
10.
ShielA. Cancer in dialysis and transplant patients. In: MorrisPJ, ed. Kidney Transplantation Principles and Practice.5th ed.Philadelphia, Pa: WB Saunders; 2001:558–570.
11.
PennI. Some contributions of transplantation to our knowledge of cancer. Transplant Proc.1980;12:676–680.
12.
KauffmanMHMcBrideMACherikhWSSpainPCMarksWHRozaAM. Transplant tumor registry: Donor related malignancies. Transplantation.2002;74:358–362.
13.
BirkelandSAStormHH. Risk for tumor and other disease transmission by transplantation: A population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation.2002;74:1409–1413.
14.
KauffmanHMMcBrideMADelmonicoFL. First report of the United Network for Organ Sharing Transplant Tumor Registry: Donors with a history of cancer. Transplantation.2000;70:1747–1751.
15.
BuellJFTrofeJHanawayMJ. Transmission of donor cancer into cardiothoracic transplant recipients. Surgery.2001;130:660–668.
16.
FengSBuellJFCherikhWS. Organ donors with positive viral serology or malignancy: Risk of disease transmission by transplantation. Transplantation.2002;74:1657–1663.
17.
LefrancoisNTouraineJLCantarovichD. Transmission of medulloblastoma from cadaver donor to three organ transplant recipients. Transplant Proc.1987;19(1 pt 3):2242.
18.
StephensJKEversonGTElliottCL. Fatal transfer of malignant melanoma from multiorgan donor to four allograft recipients. Transplantation.2000;70:232–236.
PennI. Transmission of cancer from organ donors. Ann Transplant.1997;2:7–12.
21.
PennI. Transmission of cancer with donor organs. Transplant Proc.1988;20:739–740.
22.
BuellJFTrofeJSethuramanG. Donors with central nervous system malignancies: Are they truly safe?Transplantation.2003;76:340–343.
23.
ConlonPJSmithSR. Transmission of cancer with cadaveric donor organs. J Am Soc Nephrol. July 1995;6:54–60.
24.
DetryOHonorePJacquetNMeurisseM. Management of recipients of hepatic allografts harvested from donors with malignancy diagnosed shortly after transplantation. Clin Transplant.1998;12:579–581.
25.
KauffmanHMMcBrideMACherikhWSSpainPCDelmonicoFL. Transplant tumor registry: Donors with central nervous system tumors. Transplantation.2002;73:579–582.
26.
ChuiAKHerberttKWangLS. Risk of tumor transmission in transplantation from donors with primary brain tumors: An Australian and New Zealand registry report. Transplant Proc.1999;31:1266–1267.
27.
PennI. De novo malignances in pediatric organ transplant recipients. Pediatr Transplant. February 1998;2:56–63.
28.
PennI. Neoplastic complications of organ transplantation. In: GinnsLCCosimiABMorrisPJ, eds. Transplantation.Malden, United Kingdom: Blackwell Science; 1999:770–786.
29.
PennI. Why do immunosuppressed patients develop cancer?Crit Rev Oncog. January 1989;1:27–52.
30.
EuvrardSKanitakisJClaudyA. Skin cancers after organ transplantation. N Engl J Med.2003;348:1681–1691.
31.
PennI. Cancers in renal transplant recipients. Adv Ren Replace Ther.2000;7:147–156.
32.
KasiskeBLVazquezMAHarmonWE. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol.2000;11(suppl 15):S1–86.
33.
PennI. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl.1998;12:147–158.
34.
PennI. Post-transplant malignancy: The role of immunosuppression. Drug Saf.2000;23:101–113.
35.
SheilAGDisneyAPMathewTHLivingstonBEKeoghAM. Lymphoma incidence, cyclosporine, and the evolution and major impact of malignancy following organ transplantation. Transplant Proc.1997;29:825–827.
36.
KiberdBAKeough-RyanTClaseCM. Screening for prostate, breast and colorectal cancer in renal transplant recipients. Am J Transplant.2003;3:619–625.
37.
European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.3. Cancer risk after renal transplantation. Solid organ cancers: Prevention and treatment. Nephrol Dial Transplant.2002;17(suppl 4):32, 34–36.
38.
GreenM. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant.2001;1:103–108.
39.
PennI. Neoplastic complications of transplantation. Semin Respir Infect.1993;8:233–239.
40.
PayaCVFungJJNalesnikMA. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation.1999;68:1517–1525.
41.
NalesnikMAJaffeRStarzlTE. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol. October 1988;133:173–192.
42.
KnowlesDMCesarmanEChadburnA. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood.1995;85:552–565.
43.
FrizzeraGHantoDWGajl-PeczalskaKJ. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res.1981;41(11 pt 1):4262–4279.
44.
DharnidharkaVRTejaniAHHoPLHarmonWE. Posttransplant lymphoproliferative disorder in the United States: Young Caucasian males are at highest risk. Am J Transplant.2002;2:993–998.
45.
NalesnikMA. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res.2002;159:9–18.
46.
BunnapradistSVoAToyodaM. Posttransplantation lymphoproliferative disorder presenting as a unilateral leg mass 10 years after kidney transplantation. Transplantation.2002;74:1648–1651.
47.
HolmesRDSokolRJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant.2002;6:456–464.
48.
DottiGFiocchiRMottaT. Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome. Transplantation.2002;74:1095–1102.
49.
NalesnikMA. Clinicopathologic features of posttransplant lymphoproliferative disorders. Ann Transplant.1997;2:33–40.
50.
OpelzGHendersonR. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet.1993;342:1514–1516.
51.
PennI. Posttransplant malignancies in pediatric organ transplant recipients. Transplant Proc.1994;26:2763–2765.
52.
PearlmanLS. Posttransplant viral syndromes in pediatric patients: A review. Prog Transplant.2002;12:116–124.
53.
ShapiroRNalesnikMMcCauleyJ. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation.1999;68:1851–1854.
54.
BoubeniderSHiesseCGoupyCKriaaFMarchandSCharpentierB. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol.1997;10:136–145.
55.
HoMJaffeRMillerG. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation.1988;45:719–727.
56.
DharnidharkaVRSullivanEKStableinDMTejaniAHHarmonWE. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation.2001;71:1065–1068.
57.
BirkelandSAHamilton-DutoitS. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?Transplantation.2003;76:984–988.
58.
MajewskiMKoreckaMJoergensenJ. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation.2003;75:1710–1717.
59.
NepomucenoRRBalatoniCENatkunamYSnowALKramsSMMartinezOM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res.2003;63:4472–4480.
60.
TrofeJBuellJFFirstMRHanawayMJBeebeTMWoodleES. The role of immunosuppression in lymphoma. Recent Results Cancer Res.2002;159:55–66.
61.
CherikhWSKauffmanHMMcBrideMAMaghirangJSwinnenLJHantoDW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation.2003;76:1289–1293.
62.
PreiksaitisJKKeayS. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis.2001;33(suppl 1):S38–46.
63.
TsaiDEHardyCLTomaszewskiJE. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation.2001;71:1076–1088.
64.
FirstMRPeddiVR. Malignancies complicating organ transplantation. Transplant Proc.1998;30:2768–2770.
